Chicago, USA June 28-30, 2018 THE SYMPOSIUM PREVENTING CARDIOEMBOLIC STROKE AS AN INTERDISCIPLINARY TEAM. hbs.kenes.com

Transcription

1 Chicago, USA June 28-30, 2018 THE SYMPOSIUM PREVENTING CARDIOEMBOLIC STROKE AS AN INTERDISCIPLINARY TEAM hbs.kenes.com

2 The Heart & Brain Symposium offers a comprehensive guide to primary and secondary cardioembolic stroke prevention and other heart-brain conditions. Cardiologists and neurologists will benefit from a dedicated meeting on the most up-todate knowledge and tools they need as physicians, which they could not usually get at large cardiology, neurology or stroke conferences. Highlights will include interactive case studies on complicated patients that requires teamwork across the cardiology and neurology departments - including PFO, ablation and occluders - as well as debates on treatment where there is a lack of clear guidelines. The Core ORGANIZING COMMITTEE Chair Prof. Natan Bornstein, Israel Tel-Aviv University, Sackler Faculty of Medicine Prof. Marc Fisher, USA Harvard Medical School Prof. Chris Granger, USA Duke University School of Medicine Prof. Jonathan Halperin, USA Mount Sinai Medical Center M.D. Ayrton Massaro, Brazil Hospital Sirio Libanes Prof. Ralph L. Sacco, USA Miller School of Medicine, University of Miami Prof. Jeffrey Saver, USA Geffen School of Medicine at UCLA There won t be another US meeting like it in 2018! hbs.kenes.com

3 JOIN US in CHICAGO to Gain practical tools to use in your daily practice. Meet and ask YOUR questions to THE top speakers in the field. Present your latest research at a dedicated forum. Be part of a unique coming together of cardiologists and neurologists. CONFIRMED SPEAKERS include Gregory Albers Director, Stanford Stroke Center, USA Wolfram Doehner Vice Chair of the ESC Council on Stroke, Germany Philip B. Gorelick Executive Medical Director, Mercy Health Hauenstein Neurosciences,USA Jeff Healey Director of Arrhythmia Services, Hamilton Health Sciences, USA Hooman Kamel Director of the Clinical and Translational Neuroscience Unit in the Feil Family Brain and Mind Research Institute at Weill Cornell Medical College, USA We look forward to gathering together in Chicago, usa! Late-Breaking Abstract Submission Deadline: April 26, 2018 Early Registration Deadline: April 11, 2018 hbs.kenes.com

4 KEYNOTE LECTURES THE HEART FAILURE PATIENT WITH STROKE - WHAT IS IMPORTANT, WHAT IS DIFFERENT? Wolfram Doehner, Vice Chair of the ESC Council on Stroke; Univ.-Prof. for Interdisciplinary Stroke Research Charite, Germany NAVIGATE ESUS TRIAL: WHAT DID WE LEARN? Robert Hart, McMaster University, Canada ATRIAL FIBRILLATION AND STROKE: THE FIRST 100 YEARS Robert Hart, McMaster University, Canada SYMPOSIA ATRIAL FIBRILLATION DETECTION, ASSESSING THE RISK AND TREATMENT 25%-30% of all ischemic strokes are of cardio-embolic origin where 45% are related to Atrial Fibrillation (AF). Strokes due to AF are devastating ones with high rates of mortality and disability. Therefore, detecting AF, assessing the stroke risk and tailoring the right preventive treatment to an individual patient is extremely important. This session will highlight and discuss all these important issues. Advances in Detection of AF Advances in Detection of AF James Reiffel, Columbia University, USA Assessing Stroke Risk in Subjects with AF Hooman Kamel, Weill Cornell Medical Center, USA Stroke Prevention in AF: The Role of Target-Specific Oral Anticoagulants Jonathan Halperin, Mount Sinai Medical Center, USA ATRIAL CARDIOMYOPATHY Although AF is the widely discussed issue of cardio-embolic strokes other pathological conditions of the left atrium may be important as a source of embolism. This symposium will shed light on the so far "neglected" topic in cardio-embolic stroke. Atrial Cardiomyopathy Diagnostic Approaches David Tirschwell, University of Washington Medicine Comprehensive Stroke Center, USA Fibrotic Atrial Cardiomyopathy Jeffrey Goldberger, University of Miami Hospital, USA The Role of LAA Occlusion Devices in Stroke Prevention in Patients with AF Vivek Reddy, Director of Electrophysiology Laboratories at he Mount Sinai Medical Center, USA

5 COGNITION AND THE HEART Cognitive impairment due to vascular pathology of the brain- Vascular Cognitive Impairment (VCI) is an important issue. Understanding the underlying and the related risk factors of VCI as well as the effect of the heart on VCI may have an impact on prevention and treatment of this condition. This symposium will discuss this issue from various aspects. The Neurovascular Unit and Cognitive Impairment Constantino Iadecola, Feil Family Brain and Mind Research Institute, USA Hypertension, Small Vessel Disease and Cognition Ralph Sacco, Miller School of Medicine, University of Miami, USA Defining Optimal Brain Health in Adults Philip Gorelick, Mercy Health Hauenstein Neuroscience Center, USA Aortic Stenosis, TAVR and Cognition: Imaging and Clinical Findings Ronald Lazar, University of Alabama at Birmingham, USA AF AND ICH Anticoagulants (AC) are the treatment of choice for stroke prevention in AF patients. However, AC carries a risk of bleeding and especially of Intra-Cerebral Hemorrhage (ICH). Therefore, stroke prevention, acute stroke treatment of AF patients with Mechanical Thrombectomy and when to resume AC after ICH is of a major concern for the treating physician. This symposium will try to clarify these complex and problematic issues. Stroke Prevention in AF patients at High ICH Risk - Definition and Problems with Medical Management Edip Gurol, Harvard Medical School, USA Reversal Agents John Eikelboom, McMaster University, Canada Perils of Combination Anticoagulant and Antiplatelet Therapy Marc Fisher, Beth Israel Deaconess Medical Center, Harvard Medical School, USA Resuming Anticoagulation after ICH Larry Goldstein, University of Kentucky, USA ATRIAL FIBRILLATION: 3 IMPORTANT ASPECTS There are several practical aspects in the treatment of AF patients with AC. This session will deal with three of these important topics as listed below: How to Improve the Use of Anticoagulation for Stroke Prevention in AF Christopher Granger, Duke University School of Medicine, USA When to Start Anticoagulation after Acute Ischemic Stroke Natan Bornstein, Shaare Zedek Medical Center, Jerusalem, Israel Treatment of Acute Stroke in AF Patients with Mechanical Thrombectomy Gregory Albers, Stanford Stroke Center, USA

6 EMBOLIC STROKE OF UNDETERMINED SOURCE Stroke due to ESUS imposes difficult clinical dilemma for the treating physician. The magnitude of the problem, practical evaluation and treatment options will be discussed in this symposium. The Magnitude of the Problem Gorgios Tsivgoulis, University of Athens School of Medicine/The University of Tennessee Health Science Center, Greece/USA Evaluation of Patients with ESUS Jeffrey Saver, Geffen School of Medicine at UCLA, USA Treatment options Gustavo Saposnik, University of Toronto, Canada DEBATE SESSIONS PFO WHO TO CLOSE? Until recently PFO closure by endovascular procedure was not generally recommended. However, recently the results of 2 RTCs (CLOSE and REDUCE) and the long-term follow-up of the RESPECT trial were published. These results will have an impact on the current practice. The question now is not "should we close"? but "who to close"? This will be the scope of this debate. 1st Debater: Brett Cucchiara, University of Pennsylvania, USA 2nd Debater: Richard Smalling, UTHealth and Memorial Hermann Heart and Vascular Institute, USA THE BURDEN OF AF TO TRIGGER TREATMENT It is greatly accepted that patients with Embolic Stroke of Unknown Source (ESUS) should go on long-term cardiac monitoring in order to detect sub-clinical AF. However, it is still unknown what is the burden of AF that is clinically relevant to trigger treatment with anticoagulants. This debate will highlight the various opinions: "small vs. extensive" is the dilemma that will be discussed. The Burden of AF to trigger treatment 1st Debater: Jeff Healey, McMaster University, Canada 2nd Debater: Rod Passman, Northwestern Memorial Hospital, USA DISCUSSIONS COLLABORATIVE MEDICINE Wolfram Doehner, Vice Chair of the ESC Council on Stroke; Univ.-Prof. for Interdisciplinary Stroke Research Charite, Germany James Klaas, Assistant Professor of Neurology, Mayo Clinic, Rochester, USA Christopher Granger, Duke University School of Medicine, USA

7 INTERACTIVE CASE DISCUSSION Shadi Yaghi, Brown University, USA MingMing Ning, Harvard Medical School, USA Kevin Sheth, Yale School of Medicine, USA Eitan Auriel, Carmel Medical Center, Israel EDUCATIONAL SESSION BRAIN RECOVERY AFTER STROKE Medical Therapy for Post-Stroke Motor Recovery Natan Bornstein, Shaare Zedek Medical Center, Jerusalem, Israel Intracardiac Hemostasis Parameters, Endothelial Damage and Their Association with Microembolization in the Fibrillating Atrium Laszlo Csiba, University Debrecen, Hungary Neuroprotection in the Reperfusion Era Marc Fisher, Beth Israel Deaconess Medical Center, Harvard Medical School, USA View the full program here. THE SYMPOSIUM